PPHN


Also found in: Medical.
AcronymDefinition
PPHNPersistent Pulmonary Hypertension of the Newborn
PPHNPreliminary Public Health Notification
PPHNPreliminary Public Health Notification (US FDA)
PPHNPerinatal Pulmonary Hypertension of the Neonate (physiology)
PPHNProgressive Passive Heymann Nephritis (nephrology)
References in periodicals archive ?
These results indicated that VEGF played important roles in pulmonary microcirculation and that impaired eNOS-mediated relaxations may be a potential trigger of the onset of PPHN.
PPHN was diagnosed as patient with MAS and loud 2nd heart sound supported by echocardiography.
Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review.
Importantly, maternal use of pharmacologic SERT inhibitors (SSRIs) in the third trimester of pregnancy has been linked to the development of PPHN, and altered pulmonary vasculature has been proposed as a possible mechanism [22,23].
The patient continued to deteriorate with evidence of persistent pulmonary hypertension of the newborn (PPHN).
Persistent pulmonary hypertension of the newborn (PPHN) is grave, with up to 20% of affected infants dying from the disorder and survivors facing serious long-term sequelae such as chronic lung disease, seizures, and neurodevelopmental problems.
The last decade has brought much attention to the risks of fetal exposure to antidepressant medications, with numerous studies describing the risks of adverse outcomes that range from congenital malformations, persistent pulmonary hypertension of the newborn (PPHN), and neonatal adaptation syndrome, to preterm birth and spontaneous abortion.
Persistent pulmonary hypertension (PPHN): Persistent pulmonary hypertension develops as a result of insufficiency of transition to normal circulation after delivery.
Objective: To determine the risk factors for persistent pulmonary hypertension of newborns (PPHN) and their influence on mortality.
TAPVC is often mistaken as respiratory distress syndrome, pneumonia or Persistent Pulmonary Hypertension of the Newborn (PPHN).
More recently, FDA warned about the risk of an unconfirmed association of newborn persistent pulmonary hypertension (PPHN) with SSRI use.
In July 2006, the FDA issued a public health advisory regarding SSRI use during pregnancy and the possibility of persistent pulmonary hypertension (PPHN).